Renal anemia under hemodialysis
Conditions
Interventions
None listed
Sponsors
Scientific Advisory Committee (SAC)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients scheduled to start Epogin® Injection administration within one year of initiation of hemodialysis and scheduled to continue receiving Epogin® Injection for at least 180 days to treat renal anemia occurring during dialysis. Also eligible are patients scheduled to be transferred to a maintenance dialysis facility where Epogin ® Injection is available.
Exclusion criteria
Exclusion criteria: 1) Patients undergoing other types of dialysis – e.g., CAPD, HDF, or HF 2) Patients undergoing hemodialysis and another type of dialysis simultaneously 3) Patients who have undergone other types of dialysis prior to hemodialysis 4) Patients in whom dialysis has been terminated, then resumed 5) Patients who have received another erythropoietin preparation after initiation of hemodialysis 6) Patients who do not give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relationship between maintenance Hb and vital prognosis (survival) at six months after the start of Epogin® Injection administration is investigated, and the optimal target Hb is established with respect to vital prognosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) As with vital prognosis (survival), the optimal target Hb is investigated in relation to hospitalization. However, hospitalization due to testing or social purposes is excluded. (2) The effects of erythropoietin therapy during the maintenance phase on vital prognosis and hospitalization following the initiation of dialysis are investigated. | — |
Countries
Japan
Contacts
Public ContactAyako Murayama
CHUGAI PHARMACEUTICAL CO.LTD. Drug Safety Div.
Outcome results
None listed